Parmax Pharma publishes corrigendum to EGM notice

Parmax Pharma has published a corrigendum to the Notice of Extraordinary General Meeting (EGM) dated June 8, 2026, in the Financial Express, including its Gujarati edition. The corrigendum addresses specific details regarding the proposed warrant allottees and a document hyperlink for the meeting scheduled on July 2, 2026, through Video Conferencing and other Audio-Visual Means.

The company informed shareholders that the entry for Ms. Sheetal Hiren Doshi under the column "Proposed status / Category of the Allottees" in Item No. 4 of the EGM Notice was inadvertently mentioned as "Promoter". The correct classification has been updated to "Promoter Group". This change is part of the resolution concerning the Preferential Issue of Equity Shares and Convertible Warrants.

The corrigendum also rectified the hyperlink provided for the certificate from Shreyans Jain & Co., the Practicing Company Secretary. The updated link facilitates access to the certificate required under Regulation 163(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document certifies that the Preferential Issue complies with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The revised table of Proposed Warrant Allottees details the individuals involved, the number of warrants offered, and the total consideration. The total number of warrants offered is 21,45,145 for a total consideration of ₹7,82,97,793. The table clarifies the current and proposed status of each allottee, distinguishing between Promoters, Promoter Group, and Public categories.

Name of the Proposed Warrant Allottees	Type of Proposed Warrant Allottees	Maximum number of Warrants to be offered	Total Consideration (in ₹)	Current Status / Category	Proposed status / Category of the Allottees
Dhiren Chandul Shah	Individual	5,35,715	1,95,53,598	Non-Promoter Public	Promoter*
Sunil Chinubhai Shah	Individual	81,494	29,74,531	Non-Promoter Public	Promoter*
Hiren Pravin Doshi	Individual	1,92,857	70,39,281	Non-Promoter Public	Promoter*
Sheetal Hiren Doshi	Individual	21,429	7,82,159	Non-Promoter Public	Promoter Group *
Nirmal Sunilbhai Shah	Individual	1,44,715	52,82,098	Non-Promoter Public	Promoter Group*
Dhairya Dhiren Shah	Individual	1,07,143	39,10,720	Non-Promoter Public	Promoter Group*
Rupa Sunil Shah	Individual	61,363	22,39,750	Non-Promoter Public	Promoter Group*
Vijaykumar Natvarlal Shiyani	Individual	1,42,857	52,14,281	Non-Promoter Public	Promoter Group*
Kamlesh Natvarlal Shiyani	Individual	1,43,286	52,29,939	Non-Promoter Public	Promoter Group*
Abhay Chinubhai Shah	Individual	2,85,715	1,04,28,598	Non-Promoter Public	Promoter Group*
Urvi Manish Kothari	Individual	1,42,857	52,14,281	Non-Promoter Public	Public
Mili Saumil Shah	Individual	1,42,857	52,14,281	Non-Promoter Public	Public
Fredun Nariman Medhora	Individual	1,42,857	52,14,281	Non-Promoter Public	Public
TOTAL		21,45,145	7,82,97,793

The notice stated that the Acquirers and Persons Acting in Concert (PACs) shall trigger the open offer process upon completion of the preferential issue, in accordance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. All other items of the Notice of EGM and the Explanatory Statement dated June 8, 2026, remain unchanged.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.00%	+10.39%	+108.36%	+141.41%	+108.36%	+36.34%

Pradeep Gosalia has significantly reduced his shareholding in Parmax Pharma Ltd by disposing of 3,00,000 equity shares. The transaction, executed on June 18, 2026, resulted in the seller's stake dropping to 0.07% of the company's total paid-up equity share capital. The shares were transferred pursuant to a Share Purchase Agreement entered into between Rupa Sunil Shah and Abhay Chinubhai Shah.

Transaction Details

The disclosure was filed under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to the disposal, Pradeep Gosalia held 3,02,714 shares, which accounted for 8.09% of the total voting capital. Following the sale of 3,00,000 shares, the remaining holding stands at 2,714 shares.

Shareholding Pattern

The table below outlines the changes in the shareholding structure following the transaction:

Description	Number of Shares	% of Total Share Capital
Holding Before Disposal
Shares carrying voting rights	3,02,714	8.09%
Shares Sold
Shares carrying voting rights	3,00,000	8.02%
Holding After Disposal
Shares carrying voting rights	2,714	0.07%

Capital Structure

Parmax Pharma Ltd's equity share capital remained unchanged at 37,41,300 shares with a face value of ₹10 per share. The total paid-up equity share capital amounts to ₹3,74,13,000. The diluted share capital also remains at 37,41,300 shares. The seller confirmed that he does not belong to the promoter or promoter group of the company.